Lord, Abbett & Co’s Harmony Biosciences HRMY Stock Holding History

Lord, Abbett & Co’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-92,478	Closed	-$5.09M	–	595
2022 Q4	$5.09M	Buy	+92,478	New	+$5.08M	0.02%	498

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lord, Abbett & Co's HRMY Position: Q1 2023 in Review

Lord, Abbett & Co sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 92,478 shares — an estimated $5.09M sold.

Lord, Abbett & Co first reported a position in HRMY in Q4 2022 and held it in 1 quarter. The position peaked at $5.09M in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

Lord, Abbett & Co reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
Lord, Abbett & Co sold 92,478 Harmony Biosciences shares in Q1 2023, an estimated $5.09M.
Lord, Abbett & Co first reported a position in Harmony Biosciences in Q4 2022 and held it in 1 quarter.
Lord, Abbett & Co's Harmony Biosciences position peaked at $5.09M in Q4 2022.
217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Lord, Abbett & Co's 13F filing for Q1 2023, filed 12 May 2023.